It was about half a decade ago that we had emphasized the importance of rigorous administration of methotrexate after allogeneic hematopoietic stem cell transplantation (HSCT). 1 At that time, our conviction of the importance of methotrexate was based upon interpretation of limited and circumstantial data suggesting a connection between suboptimal methotrexate dosing and acute graft-versushost disease (GVHD), acute GVHD and chronic GVHD, and chronic GVHD and outcome. It is therefore gratifying to see that the Stem Cell Trialists' Collaborative Group 2 has now confirmed that indeed, 'a little methotrexate goes a long way', 1 and also agreed with our hypothesis that in the setting of a much higher T-cell lymphocyte inoculum seen with blood-derived stem cells, a seemingly trivial difference in methotrexate administration could have profound consequences for blood stem cell recipients while making limited or no impact on marrow recipients. 1 Although no direct data exist linking mucositis severity and GVHD, it is not unreasonable to expect that more severe tissue injury would be associated with greater release of inflammatory cytokines and a greater likelihood of GVHD. It could thus be argued that patients in whom scheduled day þ 11 methotrexate doses are omitted because of significant mucositis are the very patients in whom administering the day þ 11 methotrexate dose is most critical. While the current analysis 2 studied methotrexate administration on an intent-to-treat basis, it would be interesting to see the effect of the actual methotrexate dose delivered. For example, in our randomized study comparing allogeneic marrow and blood, 3 all patients received all four scheduled doses of methotrexate without any dose-modification as was specifically mentioned in the report. This was also the first study showing significantly lower relapse after the use of blood-derived stem cells compared to marrow-derived stem cells, and showed a trend towards superior disease-free survival in the initial report. 3 This difference persisted with a minimum followup of 6 years 4 ( Figure 1 ). Two other potentially important questions not addressed in this analysis are the effect of the cell dose 5 and the effect of the administration of myeloid growth factors early after transplantation. 6 In the context of the randomized study, 3, 4 we have shown that patients getting X2 Â 10 6 CD34 þ cells/kg had a lower likelihood of transplant-related mortality and higher disease-free survival compared to those getting a lower number of cells. 5 Whether the CD34 þ cell threshold chosen was 2, 3 or 4 Â 10 6 /kg, patients receiving lower cell doses had a worse outcome. 5 However, for adult patients, it is physically not possible to increase the cell dose to very high levels when using marrow. With blood, CD34 þ cell doses can reach very high levels. There is evidence to suggest that very high CD34 þ cell doses (e.g. 48 Â 10 6 /kg) can increase the incidence of GVHD and may be detrimental to outcome. 7, 8 Perhaps the 'correct' CD34 þ cell dose is a range, 6-8 Â 10 6 /kg in our experience, 9 that is still to be definitively determined, and is not a minimum threshold as has generally been thought. An additional complicating factor is the suggestion that cell doses based on ideal body weight are better predictors of outcome than those based on actual, 9 when it has been almost universal to use actual body weight for these calculations. The routine use of myeloid growth factors after allogeneic HSCT is controversial. 6 Some studies suggest it is unsafe 10 whereas others do not. 11 What compounds the problem of growth factor use in allogeneic HSCT is some degree of correlation between the use of lower amounts of methotrexate and routine administration of G-CSF to accelerate neutrophil recovery. 1 The data available to the Stem Cell Trialists' Collaborative Group may help resolve this important issue too.
We suggest analysis of the pooled data to study the effect of the actual methotrexate dose administered, the CD34 þ cell dose based on actual and ideal body weight, and G-CSF use in addition to other standard prognostic factors. The information obtained may help modify clinical practice in way that could influence survival beneficially.
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